Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations (BIOTEC)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT01153984
First received: June 16, 2010
Last updated: March 1, 2017
Last verified: February 2017
  Purpose
This open-label, single-arm, multi-center study will evaluate the progression-free survival in participants with histologically documented, advanced and/or metastatic chemotherapy naive, non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) positive mutations and receiving erlotinib treatment. The anticipated time on study treatment is until disease progression, unacceptable toxicity, withdrawal due to any reason or death.

Condition Intervention Phase
Carcinoma,Non-Small-Cell Lung
Drug: Erlotinib
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Biomarkers Impact on the Response to Treatment With Erlotinib in First Line Non-small Cell Lung Cancer With EGFR Activating Mutations - BIOTEC

Resource links provided by NLM:


Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Progression-Free Survival (PFS), as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) [ Time Frame: Baseline up to approximately 4 years ]
    PFS was the time from inclusion in the study to the date of first documented PD or death from any cause, whichever occurred first. Participants without event were censored at the date of the last tumor assessment where non-progression was documented. If a participant received a second anti-cancer therapy without prior documentation of disease progression, the participant was censored at the date of last tumor assessment before starting new chemotherapy. Analysis was performed using Kaplan-Meier method. PD was defined as at least a 20% increase in the sum of LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions.


Secondary Outcome Measures:
  • Time to Disease Progression, as Assessed by Investigator Using RECIST v1.1 [ Time Frame: Baseline up to approximately 4 years ]
    Time to disease progression was defined as the time from baseline evaluation to the first date PD was recorded. Participants without progression were censored at the date of last tumor assessment where non-progression was documented. PD was defined as at least a 20% increase in the sum of LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions.

  • Percentage of Participants With Complete Response (CR) And Partial Response (PR) as Assessed by the Investigator Using RECIST v1.1 [ Time Frame: Baseline up to approximately 4 years ]
    CR was defined as the disappearance of all target lesions, and PR was defined as at least a 30% decrease in the sum of the longest diameter compared to baseline.

  • Percentage of Participants Who Were Alive One Year After Study Treatment Initiation [ Time Frame: Year 1 ]
  • Percentage of Participants by Localization of PD, as Assessed by Investigator Using RECIST v1.1 [ Time Frame: Baseline up to approximately 4 years ]
    PD was assessed using RECIST v1.1. PD was defined as at least a 20% increase in the sum of LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions. Percentage of participants by localization of PD were reported. Localization included: Left lung inferior lobe; Para-aortic; Left lung upper lobe; Right lung inferior lobe; and Infracranial.

  • Number of EGFR Positive Participants Classified Based on Smoking Status [ Time Frame: Day 1 ]
    Participants were asked: "Have you smoked at least 100 cigarettes in your entire life?" and "Do you now smoke cigarettes every day, some days, or not at all?" Responses were grouped into three categories: Current Smoker, Former Smoker, and Non-Smoker. Participants who reported smoking at least 100 cigarettes in their lifetime and who, at the time of survey, smoked either every day or some days were defined as 'Current smoker'. Participants who reported smoking at least 100 cigarettes in their lifetime and who, at the time of the survey, did not smoke at all were defined as 'Former smoker'. Participants who reported never having smoked 100 cigarettes were defined as 'Non-smoker'.

  • Number of EGFR Positive Participants Classified Based on Type of EGFR Mutations [ Time Frame: Day 1 ]
    Participants with NSCLC have tumor associated with EGFR mutations. These mutations occur within EGFR Exons 18-21, which encodes a portion of the EGFR kinase domain.

  • Percentage of Similar EGFR Mutations Between Matched Plasma and Tumor Tissue Samples [ Time Frame: Baseline up to approximately 4 years ]

Enrollment: 23
Study Start Date: June 2011
Study Completion Date: July 2015
Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Erlotinib
Participants will receive 150 milligrams (mg) erlotinib orally daily until disease progression, unacceptable toxicity, withdrawal due to any reason or death.
Drug: Erlotinib
Erlotinib 150 mg oral doses will be administered daily.
Other Name: Tarceva

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histological documented adenocarcinoma, locally advanced - Stage IIIB, metastatic - Stage IV or recurrent non-squamous NSCLC
  • Activated EGFR mutation positive status (Exons 19 and 21) for treatment phase
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Life expectancy greater than or equal to (≥) 12 weeks
  • Evidence of disease with at least one measurable disease evaluation on Response Evaluation Criteria in Solid Tumors (RECIST)
  • Adequate hematological , liver and renal function

Exclusion Criteria:

  • Known hypersensitivity to erlotinib or any of its excipients
  • Squamous non-small cell or small cell tumors or absence of histological report
  • Neoadjuvant/adjuvant chemotherapy within 6 months prior to enrollment
  • Prior exposure to inhibitors of EGFR
  • Prior chemotherapy or treatment with another systemic anti-cancer agent for the treatment of the participant's current stage of disease
  • Any significant ophthalmologic abnormality, especially severe dry eye syndrome, keratoconjunctivitis sicca, Sjögren syndrome, severe exposure keratitis or any other disorder likely to increase the risk of corneal epithelial lesions
  • Radical radiotherapy with curative intent within 28 days prior to enrollment
  • Any active non-controlled systemic disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01153984

Locations
Romania
County Hospital Alba; Oncology
Alba Iulia, Romania, 510073
Institute Of Oncology Bucharest; Medical Oncology
Bucharest, Romania, 022338
Spitalul de Boli Cronice Sf. Luca
Bucharest, Romania, 04195
Emergency University Bucharest Hospital; Oncology Department
Bucharest, Romania, 050098
Institut of Oncology Al. Trestioreanu Bucharest; Oncology
Bucuresti, Romania, 022328
Oncology Inst. Cluj-Napoca; Cancer Dept
Cluj-Napoca, Romania, 400015
Uni Hospital St. Spiridon; Clinica Oncologie-Radiotherapie
Iasi, Romania, 6600
S.C. Life Search S.R.L; Medical Oncology Clinic
Timisoara, Romania, 300167
ONCOMED - Medical Centre
Timisoara, Romania, 300239
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01153984     History of Changes
Other Study ID Numbers: ML22606
2009-017063-42
Study First Received: June 16, 2010
Results First Received: March 1, 2017
Last Updated: March 1, 2017

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Erlotinib Hydrochloride
Endothelial Growth Factors
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Growth Substances
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 22, 2017